The Disrupt CAD III Study. Key Take Outs from Faculty

Works at The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati,... Works at The Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH, USA. Features in 9 videos on Wondr Medical. Dean Kereiakes generally speaks on Peripheral Vascular Disease (PVD), Coronary Interventions, Impella, Shockwave Lithotripsy (Coronary), and Transcatheter Aortic Valve Implantation (TAVR / TAVI). Read more Show less

Works at Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Features in 20 videos... Works at Hospital of the University of Pennsylvania, Philadelphia, PA, USA. Features in 20 videos on Wondr Medical. Howard Herrmann generally speaks on Transcatheter Aortic Valve Implantation (TAVR / TAVI), Mitral, Mitral regurgitation, MitraClip, and Structural Cardiac Interventions. Read more Show less

Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton... Consultant Interventional Cardiologist and Revascularisation Group Chair at Royal Brompton Hospital, London. His clinical focus is on use of intravascular imaging in complex PCI , CTO and cardiogenic shock. His clinical research interests focus on optical coherence tomography, calcific coronary disease and percutaneous ventricular support. Dr Hill was global co-chief investigator for the DISRUPT CAD III study and has served as UK principal investigator for multiple interventional trials. He has served as a CTO and complex PCI proctor on a global basis and works closely with OPTIMA to focus on the development of OPTIMAL PCI. He is the founding co-director of the Complete Revascularisation (CoRe) meetings held every year in London. Read more Show less

Dr. Riley is an Interventional Cardiologist specializing in the care of patients with complex and... Dr. Riley is an Interventional Cardiologist specializing in the care of patients with complex and high-risk coronary artery disease and cardiogenic shock. He focuses on the treatment of coronary chronic total occlusions, multivessel coronary artery disease (including patients turned down for CABG surgery), atherectomy, and those in need of mechanical circulatory support. He was born in Knoxville, TN and completed his undergraduate education at Furman University with a degree in Chemistry. He attended medical school at the University of Virginia and completed residency in Internal Medicine at the University of Washington. He then completed his Cardiology fellowship at Wake Forest University, during which he obtained a Masters degree in Clinical and Population Translational Science. He then returned to the University of Washington to complete his Interventional Cardiology fellowship, followed by the first ever advanced fellowship in Complex, High-Risk, and Indicated PCI and Hemodynamic Support before joining the group at Christ Hospital. He is very active in clinical research, co-edits a monthly newsletter on high-risk PCI, and enjoys speaking at national and international meetings. Read more Show less

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The... Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial. Read more Show less